计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 提供 ≥96% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
APD668是有效的GPR119激动剂,对人源GPR119和大鼠GPR119的EC50值分别为2.7 nM和33 nM。
Information
APD668 APD668 (JNJ28630368) is a potent GPR119 agonist with EC50s of 2.7 and 33 nM for human and rat forms, respectively.
Targets
human GPR119 ; rat GPR119 2.7 nM(EC50); 33 nM(EC50)
In vitro
APD668 is shown to increase adenylate cyclase activation in HEK293 cells transfected with human GPR119 (but not in non-transfected cells) in a concentration-dependent manner with an EC50 of 23 nM. APD668 also enhanced insulin release from both rat and human isolated pancreatic islets in a glucose-dependent manner. In a standard panel of around 80 known receptors and ion channels, APD668 did not show any binding in excess of 50% of control to any other proteins at concentrations up to 10 μM.
In vivo
Chronic treatment with APD668 showed that blood glucose and glycated hemoglobin (HbA1c) levels could be significantly reduced in Zucker Diabetic Fatty (ZDF) rats over several weeks of dosing. APD668 is highly bound to plasma proteins of male and female cynomolgus monkeys and humans (P99%), but was less extensively bound to male (93.0%) and female (96.6%) rats. In pharmacokinetic assessments across multiple species using single oral doses of APD668, absorption was rapid to moderate (Tmax 62 h) in mice, Sprague-Dawley (SD) rats, and monkeys, but slower in dogs (Tmax = 6 h) and showed a dose-dependent increase in rats and monkeys. In general, exposure was dose-dependent at lower doses and appeared to plateau at doses greater than 300 mg/kg. Exposure was greater in female rats compared with males. Absolute oral bioavailability was moderate to good in mice, rats, and monkeys (44–79%), but was lower in dogs (22%). The volume of distribution (Vdss) values were somewhat variable ranging from 0.1 L/kg in monkey to 2.6 L/kg in rats. Elimination, based on mean T1/2 after intravenous (iv) dosing, was rapid to moderate in mice, rats, dogs, and monkeys (0.8-3.9 h). The pharmacokinetic profile of APD668 in Zucker fa/fa rats was somewhat different from that in SD rats. After oral administration, the tmax and T1/2 were longer, and the AUC and the oral bioavailability were greater in the Zucker compared with the SD rats. Following iv administration, the Zucker rats also had larger AUC values, longer T1/2 values and greater Vdss values.
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 唑类 |
| 亚类(Subclass) | 吡唑类 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 苯基吡唑类 |
| 其他上位类(Alternative Parents) | 吡唑并[3,4-d]嘧啶 哌啶羧酸 苯磺酰基化合物 烷基芳基醚 氟苯类 嘧啶和嘧啶衍生物 芳基氟化物 砜类 氨基甲酸酯 杂芳族化合物 氮杂环化合物 羰基化合物 有机氮化合物 有机氟化物 有机氧化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 芳基醚 - 芳香族杂多环化合物 - 芳基氟化物 - 芳基卤化物 - 氮杂环 - 苯磺酰基 - 苯基化合物 - 脲酸酯 - 羰基 - 乙醚 - 氟萘 - 卤苯 - 杂芳香族化合物 - 烃衍生物 - 单环苯基基团 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氟化物 - 有机卤化物 - 有机氮化合物 - 有机氧化合物 - 有机硫化合物 - 苯基吡唑 - 哌嗪 - 哌嗪-3,4-二羟基-2-哌嗪酮 - 吡唑并[3,4-d]嘧啶 - 吡唑并嘧啶 - 嘧啶 - 磺酰基 - 磺酰基 |
| 描述(Description) | 该化合物属于苯基吡唑类有机化合物。这类化合物具有苯基吡唑骨架,即吡唑基团与苯基相连的结构。 |
| 外部描述符(External Descriptors) | 暂无 |
| ALogP | 2.67 |
|---|---|
| hba_count | 8 |
| Rotatable Bond | 6 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
H302: 吞食有害
H315: 引起皮肤刺激
H319: 引起严重眼睛刺激
H335: 可能引起呼吸道刺激
P264: 处理后要彻底洗手。
P270: 使用本产品时,请勿进食、饮水或吸烟。
P301+P312+P330: 如误吞咽:如感觉不适,呼叫急救中心/医生。漱口